布普罗和米尔塔萨平在重大抑郁症中产生了一致的差异效应
1Department of Biomedical Informatics, University of Pittsburgh, 5607 Baum Blvd, Room 523, Pittsburgh, PA 15206, United States of America; Department of Psychiatry, University of Pittsburgh, 3811 O'Hara St, Pittsburgh, PA 15213, United States of America.
Journal of affective disorders
|May 31, 2025
概括
监督的瓦里马克斯 (SV) 分析显示,针对不同抑郁症症状,抗抑郁药具有特定的益处. 布普罗在高睡眠和疲劳方面表现出色,而米尔塔扎平在失眠和食欲变化方面更好.
科学领域:
- 精神病学和临床神经科学
- 计算精神病学是一种计算精神病学.
- 药物基因组学 药物基因组学
背景情况:
- 大型抑郁症呈现出多种不同的症状和对抗抑郁药物的反应.
- 目前的临床试验经常使用总结结果,掩盖个体症状水平治疗差异.
研究的目的:
- 应用监督Varimax (SV) 算法来识别症状尺寸,以区分抗抑郁药的有效性.
- 在多个临床试验中验证这些发现.
主要方法:
- 监督Varimax (SV) 算法用于分析症状级别的抗抑郁药效应.
- 分析了来自STAR*D和CO-MED试验的数据.
- 为了统计学意义,使用了带有家族错误率 (FWER) 校正的转换试验.
主要成果:
- 在SV中,发现了诸如布洛普里昂和米尔塔扎类抗抑郁药物之间的显著症状特异性差异.
- 布普罗改善了高睡眠症,而米尔塔扎平对失眠和食欲相关症状更有效.
- 综合治疗也显示出补充性,症状特异性的益处.
结论:
- 监督Varimax (SV) 算法提供了一个统计严格的方法,以在症状水平上区分抗抑郁药的效果.
- 研究结果表明,布洛是治疗高睡眠,疲劳和体重增加的最佳药物,而米尔塔扎是治疗失眠和减肥的最佳药物.
- 这种方法提供了一个临床相关的框架,用于根据个体患者症状概况指导抗抑郁药的选择.
更多相关视频
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
380
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
380
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
626
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
626
Antidepressant Drugs: Overview
804
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
804
Depressive Disorders: MDD and Dysthymia
225
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
225
Sedatives and Hypnotics Drugs: Miscellaneous Agents
249
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
249
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
314
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
314


